# Olaparib and Radiotherapy in Head and Neck Cancer

> **NCT02229656** · PHASE1 · UNKNOWN · sponsor: **The Netherlands Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Laryngeal Cancer Stage II
- Laryngeal Cancer Stage III
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms

## Interventions

- **RADIATION:** radiotherapy
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02229656
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09-24
- **Primary completion:** 2020-01-14
- **Final completion:** 2024-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229656, "Olaparib and Radiotherapy in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02229656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*